Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1094.0000 -15.90 (-1.43%)
NSE Sep 24, 2025 15:30 PM
Volume: 1.2M
 

1094.00
-1.43%
Motilal Oswal
13 November 2019 by the US (+27.3% YoY to INR28b) and Europe (+21.2% YoY to INR14b). New launches, higher sales in existing products and also sales from acquired entity provided momentum during the quarter. Growth markets grew at a subdued rate of 3.8% YoY to INR3b, while ARV/API sales were down 2.5%/1.3% YoY to INR2.4b/INR8b. YoY to 57.7% due to a favorable mix (product/geographical). However, EBITDA margin shrank 80bp YoY to 20.8% (in-line) due to higher staff cost/other expenses (+90bp/+100bp YoY). EBITDA grew 14% YoY to INR11.7b (in-line).
Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.4
More from Aurobindo Pharma Ltd.
Recommended